논문KCI 등재
Letter to the editor on “Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target”
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
관련 논문AI추천
Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”Ahmed O. Kaseb, Ji Hoon Kim, Ju-Seog Lee, Peng Wei, Sung Hwan Lee, Sunyoung S. Lee, Sun Young Yim대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Correspondence to editorial on “Development and validation of a stromal-immune signature to predict prognosis in intrahepatic cholangiocarcinoma”Shao-Lai Zhou, Yu-Hang Ye대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”Ahmed O. Kaseb, Ji Hoon Kim, Ju-Seog Lee, Sung Hwan Lee, Sunyoung S. Lee, Sun Young Yim대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”Ahmed O. Kaseb, Ji Hoon Kim, Ju-Seog Lee, Sung Hwan Lee, Sunyoung S. Lee, Sun Young Yim대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”Hiroaki Kanzaki, Yujin Hoshida대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Radiomics and radiogenomics of primary liver cancersDavid Shinkuo Lu, Ely Richard Felker, Neema Jamshidi, Steven Satish Raman, Woo Kyoung Jeong대한간학회 · Clinical and Molecular Hepatology2019 · 제25권 제1호
이 간행물의 다른 논문 (76건)
2025 KASL clinical practice guidelines for management of hepatitis CEun Sun Jang, Eun Ju Cho, Chang Hun Lee, Do Seon Song, Nae-Yun Heo, Jae Yoon Jeong, Jung Gil Park, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jungpp. 1-52Critical considerations in evaluating the therapeutic potential of HK-660S for primary sclerosing cholangi tis: Letter to the editor on “Safety and efficacy of HK 660S in patients with primary sclerosing cholangitis: a randomized double-blind phase 2a trial”Yizi He, Haifeng He, Qi Liang, Yongzhi Xiepp. 1-3Letter to the editor on “Current burden of steatotic liv er disease and fibrosis among adults in the United States, 2017–2023”Sisi Yang, Zhenxuan Mapp. 4-6Letter to the editor on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcino ma: a nationwide cohort study”Xiaodi Yang, Zhongqing Qian, Qiong Wang, Fuliang Chen, Xiaojing Wang, Deyan Chenpp. 7-9Letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”Juan Yang, Xinyi Li, Sheng Zhengpp. 10-12